Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex
Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood
HELOCYTE ANNOUNCES CORPORATE AND CLINICAL MILESTONES
FORTRESS BIOTECH (f/k/a Coronado Biosciences) FORMS NEW SUBSIDIARY, HELOCYTE, INC. (f/k/a DiaVax Biosciences) TO DEVELOP NOVEL IMMUNOTHERAPIES FOR CYTOMEGALOVIRUS
